

Modified Form PTO-1449 LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	Atty. Docket No.	Serial No.
	A-451N	10/825,898
	Applicant Boyle	
	Filing Date April 15, 2004	Group

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
	A1						
	A2						
	A3						
	A4						
	A5						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES NO
	B1	0 784 093 A1	1997-07-16	EP			
	B2						
	B3						
	B4						

OTHER DOCUMENTS (Including Publisher, Author, Title, Date, Pertinent Pages, Etc.)

	C1	Bharti and Aggarwal, "Ranking the role of RANK ligand in apoptosis", Apoptosis, 9: 677-690 (2004)
	C2	Chopin et al., "Synergistic induction of apoptosis in breast cancer cells by cotreatment with butyrate and TNF-alpha, TRAIL, or anti-Fas agonist antibody involves enhancement of death receptors' signaling and requires P21 waf1", Exp. Cell Res., 298: 560-573 (2004)
	C3	Collin et al., "Constitutive expression of osteoclast-stimulating activity by normal clonal osteoblast-like cells: effects of parathyroid hormone and 1,25-dihydroxyvitamin D3", Endocrinology, 131(3): 1181-1187 (1992)
	C4	Lacey et al., "Interleukin 4, interferon-gamma, and prostaglandin E impact the osteoclastic cell-forming potential of murine bone marrow macrophages", Endocrinology, 136(8): 2367-2376 (1995)
	C5	Roitt et al., Immunology, 3rd Ed., MOSBY, ISBN: 0-397-44765-5, (1993)
	C6	Takahashi et al., "Osteoblastic cells are involved in osteoclast formation", Endocrinology, 123(5): 2600-2602 (1996)
	C7	Theill et al., "RANK-L and RANK: T Cells, Bone Loss, and Mammalian Evolution", Annu. Rev. Immunol., 20: 795-823 (2002)
	C8	Yasuda et al., "Identity of Osteoclastogenesis Inhibitory Factor (OCIF) and Osteoprotegerin (OPG): A Mechanism by which OPG/OCIF Inhibits Osteoclastogenesis in Vitro", Endocrinology, 139(3): 1329-1337 (1998)
	C9	Amendment and Response to Office Action Mailed September 19, 2008, filed March 10, 2009 for USSN 10/408,901
	C10	Notice of Allowance and Fee(s) Due Mailed September 28, 2009 for USSN 10/408,901
	C11	Part B - Issue Fee(s) Transmittal filed December 22, 2009 for USSN 10/408,901

EXAMINER:

Date Considered:

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Modified Form PTO-1449

Atty. Docket No.

A-451N

Serial No.

10/825,898

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Boyle

Filing Date

April 15, 2004

Group

	C12	Lacey et al., "Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation", Cell, 93: 165-176 (1998)
	C13	Response to Notice of Noncompliant Amendment and Preliminary Amendment filed August 21, 2009 for USSN 09/791,153
	C14	Office Communication Mailed September 2, 2009 for USSN 11/981,664
	C15	Response filed December 2, 2009 for USSN 11/981,664 including extension of time, electronic fee transmittal, and electronic acknowledgement receipt
	C16	Office Communication Mailed February 2, 2010 for USSN 11/981,664
	C17	Response filed February 16, 2010 for USSN 09/211,297 including exhibits A through H (Shown above in C9-C16), extension of time, IDS and SB08a Form, RCE transmittal, electronic fee transmittal and electronic acknowledgement receipt

EXAMINER:

Date Considered:

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.